Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients  

作　　者：Bo Jin Yutong Ma Qian Wu Qiuxiang Ou Yang Shao Shun Xu 

机构地区：[1]Department of Medical Oncology,The First Hospital of China Medical University,Shenyang,Liaoning 110001,China [2]Geneseeq Research Institute,Nanjing Geneseeq Technology Inc.,Nanjing,Jiangsu 210000,China [3]School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China [4]Department of Thoracic Surgery,The First Hospital of China Medical University,Shenyang,Liaoning110001,China

出　　处：《Genes & Diseases》2024年第1期76-79,共4页基因与疾病（英文）

基　　金：approved by the Ethics Committee for the First Hospital of China Medical University(No.20180551230).

摘　　要：MET gene alterations in lung cancer patients mainly include exon 14 skipping and gene amplification,which are the key therapeutic targets and drive resistance to tyrosine kinase inhibitors(TKls).1 However,the structural variants of MET,such as MET fusions,are much rarer(0.26%),as reported in a Chinese non-small cell lung cancer(NSCLC)cohort.2 Several recurrent MET fusions,such as KIF5B-MET and HLADRB1-MET,were reported as oncogenic drivers and showed favorable responses to crizotinib.

关 键 词：LUNG patients alterations 

分 类 号：R73[医药卫生—肿瘤]